文献速递心力衰竭与心肌病血脂与心血管预防

儿童接种BNT162b2 mRNA新冠疫苗后心肌炎关联的病例系列研究

Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children.
PubMed 文献 · JAMA Cardiol · 2021-01-01

该单中心病例系列纳入2021年5月1日至7月15日期间住院的15例19岁以下儿童,均在接种BNT162b2 mRNA新冠疫苗后30天内发生心肌炎。患者多为男性(93%),中位年龄15岁,症状始于接种后1-6天,最常见为胸痛(100%)。心脏磁共振在87%患者中显示心肌炎征象,短期随访多数症状缓解,未见重症或死亡,长期风险未知。

要点

  • 接种BNT162b2后30天内儿童可发生心肌炎,多见于男性第二剂后。
  • 心脏磁共振是诊断关键,87%患者显示心肌炎征象。
  • 短期预后良好,但长期风险未知,需更大样本长期随访。

核心结论

  • 儿童接种BNT162b2 mRNA新冠疫苗后可能发生心肌炎,本病例系列中短期病情较轻,长期风险未知。

研究设计与样本

  • 单中心儿童转诊机构的病例系列,纳入2021年5月1日至7月15日住院的19岁以下、接种BNT162b2后30天内发生心肌炎的儿童,共15例。

主要发现

  • 15例患者中14例为男性(93%),中位年龄15岁(范围12-18岁)。
  • 症状始于接种后1至6天,胸痛15例(100%),发热10例(67%),肌痛8例(53%),头痛6例(40%)。
  • 入院时所有患者肌钙蛋白升高(中位数0.25 ng/mL,范围0.08-3.15 ng/mL),峰值出现在入院后0.1至2.3天。
  • 超声心动图显示3例(20%)左室射血分数降低,5例(33%)整体纵向或环向应变异常,无患者出现心包积液。
  • 心脏磁共振显示13例(87%)符合心肌炎,包括12例(80%)晚期钆增强、2例(13%)T2加权成像区域高信号、3例(20%)细胞外容积分数升高、2例(20%)左室整体原生T1升高。

临床怎么用

  • 对接种BNT162b2后短期内出现胸痛等心脏症状的青少年,尤其男性,应警惕心肌炎并完善心电图、超声心动图和心脏磁共振检查。
  • 本病例系列中短期预后良好,但长期风险未知,临床随访需关注心脏功能及心律失常。

局限性

  • 本研究为小样本单中心病例系列,无对照人群,无法确立因果关系或估计发生率。
  • 随访时间短(出院后1至13天),长期风险未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine was authorized on May 10, 2021, for emergency use in children aged 12 years and older. Initial reports showed that the vaccine was well tolerated without serious adverse events; however, cases of myocarditis have been reported since approval. OBJECTIVE: To review results of comprehensive cardiac imaging in children with myocarditis after COVID-19 vaccine. DESIGN, SETTING, AND PARTICIPANTS: This study was a case series of children younger than 19 years hospitalized with myocarditis within 30 days of BNT162b2 messenger RNA COVID-19 vaccine. The setting was a single-center pediatric referral facility, and admissions occurred between May 1 and July 15, 2021. MAIN OUTCOMES AND MEASURES: All patients underwent cardiac evaluation including an electrocardiogram, echocardiogram, and cardiac magnetic resonance imaging. RESULTS: Fifteen patients (14 male patients [93%]; median age, 15 years [range, 12-18 years]) were hospitalized for management of myocarditis after receiving the BNT162b2 (Pfizer) vaccine. Symptoms started 1 to 6 days after receipt of the vaccine and included chest pain in 15 patients (100%), fever in 10 patients (67%), myalgia in 8 patients (53%), and headache in 6 patients (40%). Troponin levels were elevated in all patients at admission (median, 0.25 ng/mL [range, 0.08-3.15 ng/mL]) and peaked 0.1 to 2.3 days after admission. By echocardiographic examination, decreased left ventricular (LV) ejection fraction (EF) was present in 3 patients (20%), and abnormal global longitudinal or circumferential strain was present in 5 patients (33%). No patient had a pericardial effusion. Cardiac magnetic resonance imaging findings were consistent with myocarditis in 13 patients (87%) including late gadolinium enhancement in 12 patients (80%), regional hyperintensity on T2-weighted imaging in 2 patients (13%), elevated extracellular volume fraction in 3 patients (20%), and elevated LV global native T1 in 2 patients (20%). No patient required intensive care unit admission, and median hospital length of stay was 2 days (range 1-5). At follow-up 1 to 13 days after hospital discharge, 11 patients (73%) had resolution of symptoms. One patient (7%) had persistent borderline low LV systolic function on echocardiogram (EF 54%). Troponin levels remained mildly elevated in 3 patients (20%). One patient (7%) had nonsustained ventricular tachycardia on ambulatory monitor. CONCLUSIONS AND RELEVANCE: In this small case series study, myocarditis was diagnosed in children after COVID-19 vaccination, most commonly in boys after the second dose. In this case series, in short-term follow-up, patients were mildly affected. The long-term risks associated with postvaccination myocarditis remain unknown. Larger studies with longer follow-up are needed to inform recommendations for COVID-19 vaccination in this population.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Dionne A, Sperotto F, Chamberlain S, et al. Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children. JAMA Cardiol. 2021. PMID: 34374740. doi:10.1001/jamacardio.2021.3471

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。